Form 4: Oric Pharmaceuticals Director Hoerter Acquires 25,600 Stock Options

Director Steven L. Hoerter acquired 25,600 stock options in Oric Pharmaceuticals on June 12, 2024, according to a Form 4 filing.

Summary

• Steven L. Hoerter, a director of Oric Pharmaceuticals, acquired 25,600 stock options on June 12, 2024.
• The options have an exercise price of $7.90.
• The options vest on the earlier of June 12, 2025, or the day before the next annual meeting of the Issuer's stockholders following the grant date.
• The options expire on June 11, 2034.
• Following the transaction, Hoerter directly owns 25,600 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider buying can be seen as positive, this is a grant of options, which is part of standard compensation.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, such as directors and officers, and their confidence in the company's prospects.

Stakeholder Impact

• The acquisition of stock options by a director may have a slight positive impact on shareholder sentiment.

Key Dates